Development, characterization, and toxicity evaluation of amphotericin B-loaded gelatin nanoparticles

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 4, Issue 3, 2008, Pages 252-261

  Nahar, Manoj ^a   Mishra, Dinesh ^a   Dubey, Vaibhav ^a   Jain, Narendra Kumar ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

Amphotericin B; Desolvation; Gelatin; Nanoparticles; Nephrotoxicity

Indexed keywords

CHEMOTHERAPY; DRUG DELIVERY; DRUG DOSAGE; NANOPARTICLES; NANOSTRUCTURES; PROTEINS; SURFACE CHARGE; TOXICITY;

AMPHOTERICIN B; CONTROLLED-DELIVERY; CROSS LINKERS; DESOLVATION; DRUG LOADINGS; DRUG RELEASES; GELATIN; GELATIN NANO-PARTICLES; NEPHROTOXICITY; POLYDISPERSITY INDEX; REDUCED TOXICITY;

NANOSTRUCTURED MATERIALS;

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CREATININE; GELATIN; HEMOGLOBIN; NANOPARTICLE;

ANIMAL CELL; ARTICLE; BLOOD TOXICITY; CONTROLLED STUDY; COST; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SAFETY; HEMATOCRIT; HEMOLYSIS; HUMAN; HUMAN CELL; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; PH; TEMPERATURE; UREA NITROGEN BLOOD LEVEL;

AMIDOHYDROLASES; AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; BLOOD UREA NITROGEN; DRUG CARRIERS; GELATIN; HEMATOCRIT; HEMOGLOBINS; HUMANS; KIDNEY DISEASES; KINETICS; MALE; MICE; NANOPARTICLES;

EID: 49649122787     PISSN: 15499634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nano.2008.03.007     Document Type: Article

References (34)

1. Gallis H.A., Drew R.H., and Picard W.W. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 12 (1990) 308-329
2. Kleinberg M. What is the current and future status of conventional amphotericin B?. Int J Antimicrob Agents 27S (2006) S12-S16
3. Boswell G.W., Buell D., and Bekersky I. AmBisome (liposomal Amphotericin B): a comparative review. J Clin Pharmacol 38 (1998) 583-592
4. Lincopan N., Mamizuka E., and Carmona-Ribeiro A. Low nephrotoxicity of an effective amphotericin B formulation with cationic bilayer fragments. J Antimicrob Chemother 55 (2005) 727-734
5. Vieira D.B., and Carmona-Ribeiro A.M. Synthetic bilayer fragments for solubilization of amphotericin B. J Colloid Interface Sci 244 (2001) 427-431
6. Nahar M., Dutta T., Murugesan S., Asthana A., Mishra D., Rajkumar V., et al. Functional polymeric nanoparticles: an efficient and promising tool for active delivery of bioactives. Crit Rev Ther Drug Carrier Syst 23 (2006) 259-318
7. Venier-Julienne M., and Benoit J. Preparation, purification and morphology of polymeric nanoparticles as drug carriers. Pharm Acta Helv 71 (1996) 121-128
8. Espuelas M.S., Legrand P., Campanero M., Appel M., Cheron M., Gamazo C., et al. Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice. J Antimicrob Chemother 52 (2003) 419-427
9. Espuelas M.S., Legrand P., Irache J.M., Gamazo C., Orecchioni A.M., Devissaguet J.P.h., et al. Poly (e-caprolacton) nanospheres as an alternative way to reduce amphotericin B toxicity. Int J Pharm 158 (1997) 19-27
10. Tiyabbonchai W., and Limpeanchob N. Formulation and characterization of Amphotericin B-chitosan-dextran sulfate nanoparticles. Int J Pharm 329 (2007) 142-149
11. Lee C.H., Singla A., and Lee Y. Biomedical applications of collagen. Int J Pharm 221 (2001) 1-22
12. Narayami R., and Panduranga R.K. Controlled release of anticancer drug methotrexate from biodegradable gelatin microspheres. J Microencapsul 11 (1994) 69-77
13. Cascone M.G., Lazzeri L., Carmignani C., and Zhu Z. Gelatin nanoparticles produced by a simple W/O emulsion as delivery system for methotrexate. J Mater Sci Mater Med 13 (2002) 523-526
14. Leo E., Vandelli M.A., Cameroni R., and Forni F. Doxorubicin-loaded gelatin nanoparticles stabilized by glutaraldehyde: involvement of the drug in the cross-linking process. Int J Pharm 12 (1997) 75-82
15. Verma A.K., Sachin K., Saxena A., and Bohidar H.B. Release kinetics from bio-polymeric nanoparticles encapsulating protein synthesis inhibitor-Cycloheximide, for possible therapeutic applications. Curr Pharm Biotechnol 6 (2005) 121-130
16. Yeh T.K., Lu Z., Wientjes M.G., and Au J.L.S. Formulating paclitaxel in nanoparticles alters its disposition. Pharm Res 22 (2005) 867-874
17. Bajpai A.K., and Choubey J. Design of gelatin nanoparticles as swelling controlled delivery system for chloroquine phosphate. J Mater Sci Mater Med 17 (2006) 345-358
18. Sham J.O., Zhang Y., Finlay W.H., Roa W.H., and Lobenberg R. Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. Int J Pharm 28 (2004) 457-467
19. Truong-Le V.L., Walsh S.M., Schweibert E., Mao H.Q., Guggino W.B., August J.T., et al. Gene transfer by DNA-gelatin nanospheres. Arch Biochem Biophys 361 (1999) 47-56
20. Kaul G., and Amiji M. Cellular interactions and in vitro DNA transfection studies with poly(ethylene glycol)-modified gelatin nanoparticles. J Pharm Sci 94 (2005) 184-198
21. Kaul G., and Amiji M. Tumor-targeted gene delivery using poly(ethylene glycol)-modified gelatin nanoparticles: in vitro and in vivo studies. Pharm Res 22 (2005) 951-961
22. Balthasar S., Michaelis K., Dinauer N., von Briesen H., Kreuter J., and Langer K. Preparation and characterisation of antibody modified gelatin nanoparticles as drug carrier system for uptake in lymphocytes. Biomaterials 26 (2005) 2723-2732
23. Dinauer N., Balthasar S., Weber C., Kreuter J., Langer K., and von Briesen H. Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes. Biomaterials 26 (2005) 5898-5906
24. Li J.K., Wang N., and Wu X.S. Gelatin nanoencapsulation of protein/peptide drugs using an emulsifier-free emulsion method. J Microencapsul 15 (1998) 163-172
25. Coester C.J., Langer K., Van Briesen H., and Kreuter J. Gelatin nanoparticles by two-step desolvation-a new preparation method, surface modifications and cell uptake. J Microencapsul 17 (2000) 187-193
26. Leo E., Cameroni R., and Forni F. Dynamic dialysis for the drug release evaluation from doxorubicin-gelatin nanoparticles conjugates. Int J Pharm 180 (1999) 23-30
27. Echevarrya I., Barturen C., Renedo M.J., and Dios-Vieitez M.C. High-performance liquid chromatographic determination of amphotericin B in plasma and tissue application to pharmacokinetic and tissue distribution studies in rats. J Chromatogr A 819 (1998) 171-176
28. Singhai A.K., Jain S., and Jain N.K. Evaluation of an aqueous injection of ketoprofen. Die Pharmazie 52 (1997) 149-154
29. Marcondes M.C., Borelli P., Yoshida N., and Russo M. Acute Trypanosoma cruzi infection is associated with anemia, thrombocytopenia, leukopenia, and bone marrow hypoplasia: reversal by nifurtimox treatment. Microbes Infect 2 (2000) 347-352
30. Azarmi S., Huang Y., Chen H., McQuarrie S., Abrams D., Roa W., et al. Optimization of a two-step desolvation method for preparing gelatin nanoparticles and cell uptake studies in 143B osteosarcoma cancer cells. J Pharm Pharmaceut Sci 9 (2006) 124-132
31. Mazerski J., Gryzbowska J., and Borowski E. Influence of net charge on the aggregation and solubility on aggregation and solubility behaviour of amphotericin B and its derivatives in aqueous media. Eur Biophys J 18 (1990) 1-6
32. Legrand P., Romero E.A., Cohen B.E., and Bolard J. Effect of aggregation and solvent on the toxicity of amphotericin B to human erythrocytes. Antimicrob Agents Chemother 36 (1992) 2518-2522
33. Saxena A., Sachin K., Bohidar H.B., and Verma A.K. Effect of molecular weight heterogeneity on drug encapsulation efficiency of gelatin nano-particles. Coll Surf B: Biointerfaces 45 (2005) 42-48
34. Vandervoort J., and Ludwig A. Preparation and evaluation of drug loaded gelatin nanoparticles for topical ophthalmic use. Eur J Pharm Biopharm 57 (2004) 251-261